Alibaba Debuts Cloud Computer, Delivery Robots at Cloud Computing Conference
17.9.2020 05:44:00 EEST | Business Wire | Press release
Alibaba Cloud, the digital technologies and intelligence backbone of Alibaba Group, today unveiled a series of innovative products at its 12th annual Apsara Conference, highlighting the technology pioneer’s commitment in helping people adapt to the more digitized world and accelerate customers’ digital transformation during and after the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916006004/en/
Alibaba Debuts First Cloud Computer (Photo: Business Wire)
A highlight is Alibaba Cloud’s first cloud computer, a palm-sized personal computer which, despite being just about 60 grams and as light as an egg, offers high-performance computing, thanks to robust back-end cloud resources. By simply connecting the cloud computer with a normal computer screen, a user can access almost unlimited computing resources anytime, anywhere, while paying on a subscription model or for the actual cloud consumption.
“We hope our cloud computer can help people access resilient computing power whenever they need to, so they can conduct complex tasks which usually require sophisticated and powerful PCs, such as video editing, animation rendering, software development, and online customer services, with a tiny personal computer at hand now,” said Jeff Zhang, President of Alibaba Cloud Intelligence. “As working from home becomes the new normal during and after the pandemic, we believe our innovation can also help users more easily enjoy the benefits of cloud computing anytime, anywhere, in a cost-effective yet secure way.”
With robust computing power, the cloud computer can reduce the rendering time of one frame high-resolution animation from 90 minutes using a traditional PC, down to only 10 minutes. In addition, the cloud computer’s system upgrades are conducted online, saving a big chunk of the normally heavy cost of PC machine upgrades and maintenance in traditional office settings. Through Alibaba Cloud's self-developed app-streaming protocol, which is designed for synergy between the cloud and the device, users can also purchase and access licensed apps and programs such Linux and Windows as well as various office applications. All user data will be stored on cloud for datacenter-grade security and protection measures. Available initially for enterprise customers, the cloud computers will be also available for purchase by individual consumers in the near future.
Alibaba Cloud also unveiled its autonomous logistics robot for last-mile deliveries. Developed by the Alibaba DAMO Academy, the global research initiative by Alibaba Group, the delivery robot can carry 50 packages at one time and cover 62 miles (or 100 kilometres) on a single charge. It is estimated the mobile robot should be able to deliver as many as 500 packages a day to one designated community or campus, meeting the rising demand for speedy last-mile delivery in China. Online shopping is booming there, with 200 million packages delivered daily and expectations that will rise to 1 billion packages per day in the coming years.
“We are expecting a rapid spike of delivery demands brought by the thriving New Retail and local services businesses in the increasingly digitalized world,” added Zhang. “To meet the strong delivery demand for our internal business growth and for the larger society, we have been investing in smart logistics, including logistics robots, for years. We are glad to launch our latest mobile delivery robot, which will support Cainiao, Alibaba’s logistics platform, to serve communities, campuses and business parks in China. “
“Moving ahead, we aim to support the delivery needs of our local services businesses and leverage our technologies for other types of service robots, such as service robots in the airport and tourism guide robots in scenic spots.”
Supported with reinforced learning technologies, the intelligent robot can schedule its route even in a crowded environment. With proprietary, high-definition positioning technology, the robot can operate even where there’s weak or no GPS signal. Leveraging a self-developed heterogeneous computing platform, 3D Point Cloud Semantic Segmentation (PCSS) technology and deep learning, the robot can also identify obstacles and predict the intended movement of passengers and vehicles a few seconds ahead of time to enhance safety.
Consumers can use either the Cainiao or Taobao mobile apps to select a preferred timeslot during the day for delivery. The robot then arrives at the designated destination, where users retrieve their packages simply by entering a passcode they receive in the app, once the robot arrives.
A slew of cloud-native products were unveiled during the Conference:
- Cloud Lakehouse: This is the next-generation big data architecture which can deliver significant data-based values and intelligence through cross-platform computing, intelligent cache, hot/cold data separation, storage improvement and performance acceleration.
- Sandboxed-Container 2.0: Alibaba’s cloud-native container service for Kubernetes supports clusters that provide sandboxed container runtimes. The new Sandboxed-Container 2.0 enables customers to run applications in lightweight sandboxed environments with faster speeds and reduced cost of runtime resources.
- PAI-DSW 2.0: The latest Cloud-native Machine-learning Interactive Development Platform by Alibaba. It aims to provide an optimal environment for developers that is easy to use, compatible with community plug-ins and supports multi-development environments like JupyterLab, WebIDE and Terminal.
- Lindorm: The cloud-native multi-model database that is used to support the Alibaba Group ecosystem, is introduced to benefit the wider Alibaba Cloud ecosystem. Lindorm is a cloud-native database, with affordable storage and flexible processing characteristics. It is designed for applications with massive processing requirements for a mixture of unstructured, semi-structured, and structured data.
The conference, named “Leap Into the Future of Digital Intelligence,” was entirely hosted online for the first time, with over 100 virtual forums on topics ranging from cloud computing, IoT to machine learning and industrial AI solutions.
For more information about the Apsara Conference, please visit the website: https://www.alibabacloud.com/apsara-conference-2020
About Alibaba Cloud
Established in 2009, Alibaba Cloud (alibabacloud.com), the digital technology and intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916006004/en/
Contact information
Media Contact:
Crystal Liu
Crystal.liu@alibaba-inc.com
+86 18578497650
Luica Mak
luica.mak@alibaba-inc.com
+44-7905471332
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
